Bar Berta Abelis - 18 Mar 2026 Form 3 Insider Report for CollPlant Biotechnologies Ltd (CLGN)

Role: VP Legal
Signature: /s/ Bar Abelis
Issuer symbol: CLGN
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 10:16:37 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Abelis Bar Berta	VP Legal	C/O COLLPLANT BIOTECHNOLOGIES LTD., 4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK, REHOVOT, ISRAEL	/s/ Bar Abelis	18 Mar 2026	0002120230

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CLGN	Restricted Share Units						13,000	18 Mar 2026	Direct	F1, F2
holding	CLGN	Restricted Share Units						40,000	18 Mar 2026	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CLGN	Options to Purchase Ordinary Shares							18 Mar 2026	Ordinary Shares	20,000	$7.50	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.
F2	Of the restricted share units reported herein, 5,686 units are vested, and the remaining 7,314 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F3	The restricted share units shall vest over a period of 3 years as follows: 33% shall vest on November 25, 2026, and the remaining 67% shall vest in eight equal quarterly installments thereafter.
F4	13,750 options are fully vested and exercisable. The remaining 6,250 options shall vest and become exercisable in five equal quarterly installments beginning March 28, 2026 and ending March 28, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date.